P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYEL...

por Harrison, C., Rampal, R. K., Gupta, V., Verstovsek, S., Talpaz, M., Kiladjian, J.-J., Mesa, R., Kuykendall, A., Vannucchi, A., Palandri, F., Grosicki, S., Devos, T., Jourdan, E., Wondergem, M. J., Al-Ali, H. K., Buxhofer-Ausch, V., Alvarez-Larrán, A., Akhani, S., Muñoz-Carerras, R., Sheykin, Y., Colak, G., Harris, M., Mascarenhas, J.
Publicado 2022